MedPath

Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Phase 2
Terminated
Conditions
Ovarian Cancer
Interventions
First Posted Date
2008-09-25
Last Posted Date
2015-09-28
Lead Sponsor
Hellenic Oncology Research Group
Target Recruit Count
34
Registration Number
NCT00758732
Locations
🇬🇷

University Hospital of Crete, Heraklion, Crete, Greece

🇬🇷

"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

🇬🇷

Department of Medical Oncology, "Marika Iliadis" Hospital of Athens, Athens, Greece

and more 9 locations

Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Phase 2
Completed
Conditions
Adenocarcinoma of the Gastroesophageal Junction
Esophageal Cancer
Interventions
Biological: panitumumab
Drug: cisplatin
Drug: docetaxel
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
First Posted Date
2008-09-23
Last Posted Date
2016-03-11
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
70
Registration Number
NCT00757172
Locations
🇺🇸

Good Samaritan Hospital, Dayton, Ohio, United States

🇺🇸

Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States

🇺🇸

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

and more 18 locations

Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2008-09-18
Last Posted Date
2012-06-28
Lead Sponsor
University Hospital of Crete
Target Recruit Count
48
Registration Number
NCT00754351
Locations
🇬🇷

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece

🇬🇷

University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Completed
Conditions
Chemotherapeutic Agent Toxicity
Cognitive/Functional Effects
Psychosocial Effects of Cancer and Its Treatment
Fatigue
Long-term Effects Secondary to Cancer Therapy in Adults
Breast Cancer
Neurotoxicity
First Posted Date
2008-09-18
Last Posted Date
2017-11-24
Lead Sponsor
University of California, San Francisco
Target Recruit Count
81
Registration Number
NCT00755313
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Phase 2
Withdrawn
Conditions
Small Cell Lung Cancer
Interventions
First Posted Date
2008-09-18
Last Posted Date
2015-10-07
Lead Sponsor
University Hospital of Crete
Registration Number
NCT00755157
Locations
🇬🇷

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece

🇬🇷

University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece

🇬🇷

"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

Phase 3
Completed
Conditions
Prostatic Neoplasms
Interventions
First Posted Date
2008-09-01
Last Posted Date
2016-10-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1930
Registration Number
NCT00744497
Locations
🇺🇸

Maine Center For Cancer Medicine, Scarborough, Maine, United States

🇺🇸

Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States

🇺🇸

Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States

and more 40 locations

Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer

Phase 2
Completed
Conditions
Non-small-cell Lung Cancer
Interventions
First Posted Date
2008-08-26
Last Posted Date
2016-10-04
Lead Sponsor
Hellenic Oncology Research Group
Target Recruit Count
50
Registration Number
NCT00741195
Locations
🇬🇷

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece

🇬🇷

University Hospital of Heraklion, Heraklion, Crete, Greece

🇬🇷

"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 7 locations

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Phase 3
Terminated
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Placebo
Drug: ASA404
Drug: docetaxel
First Posted Date
2008-08-20
Last Posted Date
2020-12-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
900
Registration Number
NCT00738387
Locations
🇺🇸

UT Southwester Med Ctr at Dallas, Dallas, Texas, United States

🇺🇸

Texas Cancer Center - Denton, Denton, Texas, United States

🇺🇸

Longview Cancer Center, Longview, Texas, United States

and more 87 locations

Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

Phase 2
Completed
Conditions
Gastric Cancer
Adenocarcinoma of the Esophagogastric Junction
Interventions
First Posted Date
2008-08-19
Last Posted Date
2012-09-19
Lead Sponsor
Krankenhaus Nordwest
Target Recruit Count
143
Registration Number
NCT00737373
Locations
🇩🇪

Krankenhaus Nordwest, Frankfurt, Germany

First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

First Posted Date
2008-08-18
Last Posted Date
2011-02-24
Lead Sponsor
Yonsei University
Target Recruit Count
117
Registration Number
NCT00736814
Locations
🇰🇷

Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath